Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasm of Uncertain Malignant Potential 1Glioma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 16aldesleukin 14fludarabine 12fludarabine phosphate 11Interleukin-2 10montanide ISA 51 3Whole-Body Irradiation 2Radiation 2MART-1 Antigen 2Gefitinib 2sargramostim 1pembrolizumab 1peginterferon alfa-2a 1incomplete Freund's adjuvant 1flt3 ligand protein 1endonuclease V, phage T4 1Surgical Procedures, Operative 1Semaxinib 1Radiotherapy 1Peptides 1Lapatinib 1Interleukin-15 1Interleukin-12 1Early Intervention, Educational 1Deoxyribonuclease (Pyrimidine Dimer) 1Dasatinib 1Congresses as Topic 1Cholecalciferol 1B3(Fv)-PE38KDEL recombinant immunotoxin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Skin Neoplasms × peginterferon alfa-2a × Clear all
NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
16 enrolled
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡